BACKGROUND/AIM: The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in first-line treatment of elderly patients with advanced lung cancer who were unfit for polychemotherapy. Progression-free survival, response rate and overall survival were secondary end-points. PATIENTS AND METHODS: Seventy-six patients received 50 mg of oral vinorelbine three times per week, until disease progression, patient refusal or unacceptable toxicity. Patients were evaluated for response and toxicity after one cycle of chemotherapy. The treatment was considered feasible with a grade 3/4 toxicity rate lower than 20%. RESULTS: Clinical benefit was observed in 50% of patients. Median overall survival was 8.0 months. Grade 1/2 toxicity was observed in 53 patients (69.7%), grade 3 toxicity in eight patients (10.5%). One patient had grade 4 diarrhea. CONCLUSION: Metronomic oral vinorelbine is safe in elderly patients, allowing for long-term disease stabilization with optimal patient compliance. Copyright
BACKGROUND/AIM: The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in first-line treatment of elderly patients with advanced lung cancer who were unfit for polychemotherapy. Progression-free survival, response rate and overall survival were secondary end-points. PATIENTS AND METHODS: Seventy-six patients received 50 mg of oral vinorelbine three times per week, until disease progression, patient refusal or unacceptable toxicity. Patients were evaluated for response and toxicity after one cycle of chemotherapy. The treatment was considered feasible with a grade 3/4 toxicity rate lower than 20%. RESULTS: Clinical benefit was observed in 50% of patients. Median overall survival was 8.0 months. Grade 1/2 toxicity was observed in 53 patients (69.7%), grade 3 toxicity in eight patients (10.5%). One patient had grade 4 diarrhea. CONCLUSION: Metronomic oral vinorelbine is safe in elderly patients, allowing for long-term disease stabilization with optimal patient compliance. Copyright
Authors: Felice Pasini; Carmen Barile; Donatella Caruso; Yasmina Modena; Anna Paola Fraccon; Laura Bertolaso; Daniela Menon; Francesca La Russa; Giorgio Crepaldi; Antonio Bononi; Roberto Spezzano; Roberto Padrini; Giuseppe Corona; Milena Gusella Journal: Invest New Drugs Date: 2018-06-28 Impact factor: 3.850
Authors: A Camerini; G L Banna; S Cinieri; A Pezzuto; M Mencoboni; F Rosetti; A Figueiredo; P Rizzo; A Ricci; L Langenhoven; A Santo; A Addeo; D Amoroso; F Barata Journal: Clin Transl Oncol Date: 2018-11-17 Impact factor: 3.405
Authors: Vittorio Gebbia; Marco Maria Aiello; Giuseppe Banna; Giusi Blanco; Livio Blasi; Nicolò Borsellino; Dario Giuffrida; Mario Lo Mauro; Gianfranco Mancuso; Dario Piazza; Giuseppina Savio; Hector Soto Parra; Maria Rosaria Valerio; Francesco Verderame; Paolo Vigneri Journal: Ecancermedicalscience Date: 2020-09-29
Authors: David Rossi; Paolo Lippe; Marco Bruno Luigi Rocchi; Donatella Sarti; Vincenzo Catalano; Francesco Graziano; Paolo Giordani; Annamaria Baldelli; Stefano Luzi Fedeli; Luca Imperatori; Gianluca Laici; Claudia Cappelletti; Tiziana Tamburrano; Raffaella Bracci; Paolo Alessandroni Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155
Authors: Antonino C Tralongo; Roberto S Fratamico; Chiara Russo; Andrea Sbrana; Andrea Antonuzzo; Marco Danova Journal: Geriatrics (Basel) Date: 2021-04-15